IGALMI (dexmedetomidine film)

Medical Administration – sublingual 

Diagnosis considered for coverage:
  • Indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults
  • Limitations of Use:
    • The safety and effectiveness of Igalmi have not been established beyond 24 hours from the first dose
Coverage Criteria:

For diagnosis of agitation associated with schizophrenia or bipolar I or II disorder:

  • Dose does not exceed FDA label maximum dose:
    • Mild or moderate agitation: 240 mcg daily
    • Severe agitation: 360 mcg daily; AND
  • Documented diagnosis of schizophrenia OR bipolar I or II disorder; AND
  • Patient is 18 years and older; AND
  • Used for the treatment of acute agitation; AND
  • Patient has tried and failed, has a contraindication or intolerance to at least two products used in acute agitation (e.g., olanzapine, ziprasidone); AND
  • Patient is managed with maintenance medication for their underlying disorder (e.g., aripiprazole, olanzapine, quetiapine, lithium, valproic acid)
Coverage Duration: 
  • 14 days
Authorization is not covered for the following: 

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information: 
  • Igalmi should be administered under the supervision of a healthcare provider. A healthcare provider should monitor vital signs and alertness after Igalmi administration to prevent falls and syncope
  • If agitation persists after the initial dose, up to two additional doses may be administered at least two hours apart
  • The safety and effectiveness of Igalmi is not determined past 24 hours from the initial dose
Policy Updates:
  • 12/1/2022 – New policy approved by P&T
References:
  • Wilson, M., Pepper, D. et al. The Psychopharmacology of Agitation: Consensus Statement of the American Association for Emergency Psychiatry Project BETA Psychopharmacology Workgroup. West J Emerg Med. 2012 Feb; 13(1): 26–34. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3298219/. Accessed June 6, 2022. 
  • Garriga M, Pacchiarotti I, Kasper S, Zeller SL, Allen MH, Vazquez G, et al. Assessment and management of agitation in psychiatry: expert consensus. World J Biol Psychiatry. (2016) 17:86–128. doi: 10.3109/15622975.2015.1132007. Accessed June 6, 2022. 
  • Zeller, S., Citrome, L. Managing Agitation Associated with Schizophrenia and Bipolar Disorder in the Emergency Setting. West J Emerg Med. 2016 Mar; 17(2): 165–172. doi: 10.5811/westjem.2015.12.28763. accessed June 6, 2022. 
  • Miller, J. Managing acute agitation and aggression in the world of drug shortages. Mental Health Clinician (2021) 11 (6): 334–346. https://doi.org/10.9740/mhc.2021.11.334. Accessed June 6, 2022. 
  • Schleifer, J. Management of acute agitation in psychosis: an evidence-based approach in the USA. Jan 2, 2018. Available at https://www.cambridge.org/core/journals/advances-in-psychiatric-treatment/article/management-of-acute-agitation-in-psychosis-an-evidencebased-approach-in-the-usa/AC36BE73F3238B40EBDFC719B62D93E6. Accessed June 6, 2022. 
  • Roppolo, L., Morris, D. et al. Improving the management of acutely agitated patients in the emergency department through implementation of Project BETA (Best Practices in the Evaluation and Treatment of Agitation). https://doi.org/10.1002/emp2.12138. Accessed June 6, 2022. 
  • Zyprexa Prescribing Information. Lilly USA, LLC. Indianapolis, IN. February 2022. 
  • Risperdal Prescribing Information. Janssen Pharmaceuticals, Inc. Titusville, NJ. March 2022.. 
  • Geodon Prescribing Information. Pfizer Inc. New York, NY. February 2022. 
  • Abilify Prescribing Information. Otsuka America Pharmaceutical, Inc. Rockville, MD. August 2021. 
  • Seroquel Prescribing Information. AstraZeneca Pharmaceuticals, LP. Wilmington, DE. January 2022. 
  • Saphris Prescribing Information. Breckenridge Pharmaceuticals, Inc. Berlin, CT. July 2021. 
  • Igalmi Prescribing Information. BioXcel Therapeutics, Inc. New Haven, CT. April 2022. 
  • Marder, S. Uptodate. Psychosis in adults: Initial management. Available at https://www.uptodate.com/contents/psychosis-in-adults-initial-management?sectionName=INITIAL%20MANAGEMENT&search=AGITITAION%20IN%20SCHIZOPHRENIA&topicRef=14805&anchor=H4035521878&source=see_link#H4035521878. Accessed June 6, 2022. 

Last review date: December 1, 2022

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone